MX2016014179A - Derivados quinazolindiona farcologicamente activos. - Google Patents
Derivados quinazolindiona farcologicamente activos.Info
- Publication number
- MX2016014179A MX2016014179A MX2016014179A MX2016014179A MX2016014179A MX 2016014179 A MX2016014179 A MX 2016014179A MX 2016014179 A MX2016014179 A MX 2016014179A MX 2016014179 A MX2016014179 A MX 2016014179A MX 2016014179 A MX2016014179 A MX 2016014179A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmacologically active
- quinazolinedione derivatives
- quinazolinedione
- derivatives
- positive allosteric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Los compuestos de la fórmula (I), en donde R1-8 son como se define en las reivindicaciones, exhiben un efecto modulador GABAB alostérico positivo y de esta forma son útiles como moduladores alostéricos positivos del receptor GABAB.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20140133 | 2014-05-09 | ||
PCT/FI2015/000020 WO2015169999A1 (en) | 2014-05-09 | 2015-05-08 | Pharmacologically active quinazolinedione derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016014179A true MX2016014179A (es) | 2017-02-16 |
Family
ID=53276169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016014179A MX2016014179A (es) | 2014-05-09 | 2015-05-08 | Derivados quinazolindiona farcologicamente activos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20170137387A1 (es) |
EP (1) | EP3140301A1 (es) |
JP (1) | JP2017514918A (es) |
KR (1) | KR20170002626A (es) |
CN (1) | CN106414430A (es) |
AR (1) | AR100360A1 (es) |
AU (1) | AU2015257540A1 (es) |
CA (1) | CA2945217A1 (es) |
MX (1) | MX2016014179A (es) |
RU (1) | RU2016148170A (es) |
TW (1) | TW201623257A (es) |
WO (1) | WO2015169999A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI690526B (zh) * | 2015-05-20 | 2020-04-11 | 大陸商廣東衆生睿創生物科技有限公司 | 羥基嘌呤類化合物及其應用 |
CN107614501B (zh) | 2015-05-20 | 2020-01-14 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
BR112017024719B1 (pt) * | 2015-05-20 | 2023-12-05 | Guangdong Raynovent Biotech Co., Ltd | Compostos de hidroxil purina e seu uso |
CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
CN109776434B (zh) * | 2019-03-20 | 2022-01-28 | 中南大学 | 3-苄基-6-酰氨基-2,4-(1h,3h)-喹唑啉二酮衍生物及其合成方法和用途 |
CN110003037B (zh) * | 2019-05-06 | 2022-04-12 | 苏州山青竹生物医药有限公司 | 一种制备2-氨基-3,5-二氯-n-异丙基苯甲酰胺的方法 |
CN114671878B (zh) * | 2020-12-25 | 2023-08-04 | 广东东阳光药业有限公司 | 取代的含氮双环化合物及其用途 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8524663D0 (en) | 1985-10-07 | 1985-11-13 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
US6200976B1 (en) | 1998-04-17 | 2001-03-13 | Boehringer Ingelheim Pharma Kg | Antithrombotic quinoxazolines |
WO2004007469A1 (en) | 2002-07-12 | 2004-01-22 | Warner-Lambert Company Llc | New alkynylated quinazolin compounds as mmp-13 inhibitors |
FR2837201A1 (fr) * | 2002-03-18 | 2003-09-19 | Servier Lab | Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE10235225B3 (de) | 2002-08-01 | 2004-01-22 | Albert-Ludwigs-Universität Freiburg | Verfahren zur Durchführung chemischer Reaktionen unter Beteiligung von an fluorierten Trägermaterialien über Fluor-Fluor-Wechselwirkungen adsorbierten Verbindungen, fluoriertes Trägermaterial sowie die Verwendung des Trägermaterials |
US7625909B2 (en) | 2003-05-23 | 2009-12-01 | Novartis Vaccines And Diagnostics, Inc. | Substituted quinazolinone compounds |
WO2005094828A1 (en) | 2004-03-02 | 2005-10-13 | F. Hoffmann-La Roche Ag | 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy |
SE0401653D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
CA2586066A1 (en) | 2004-11-01 | 2006-05-11 | Parichehr Malherbe | Quinoline as allosteric enhancers of the gaba-b receptors |
CN101120003B (zh) | 2004-12-17 | 2010-06-16 | 弗·哈夫曼-拉罗切有限公司 | 作为gaba-b的别构增强剂的噻吩并-吡啶衍生物 |
CN101189208A (zh) | 2005-06-02 | 2008-05-28 | 弗·哈夫曼-拉罗切有限公司 | 作为gaba-b增强剂的3-甲磺酰基喹啉 |
GB0512844D0 (en) | 2005-06-23 | 2005-08-03 | Novartis Ag | Organic compounds |
ATE480529T1 (de) | 2005-07-28 | 2010-09-15 | Hoffmann La Roche | 2-hydroxy-propionsäure-derivate und 3-hydroxy- benzofuran-2-on-derivate mit affinität für den gaba-b-rezeptor |
CA2632020A1 (en) | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Imidazoles as gaba-b receptor modulators |
US7745474B2 (en) | 2005-12-23 | 2010-06-29 | Astrazeneca Ab | Imidazole derivatives for the treatment of gastrointestinal disorders |
KR20080080214A (ko) | 2005-12-23 | 2008-09-02 | 아스트라제네카 아베 | 헤테로시클릭 gaba-b 조절제 |
US20090062365A1 (en) | 2005-12-23 | 2009-03-05 | Udo Bauer | Pyrazoles for the Treatment of GERD and IBS |
AU2006327317B2 (en) | 2005-12-23 | 2010-11-25 | Astrazeneca Ab | GABA-B receptor modulators |
JP2009542628A (ja) * | 2006-07-05 | 2009-12-03 | コーリア リサーチ インスティテュート オブ ケミカル テクノロジー | 新規な置換−1h−キナゾリン−2,4−ジオン誘導体、その製造方法及びそれを含む薬学的組成物 |
GB0622472D0 (en) | 2006-11-10 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel heterocyclic derivatives |
WO2008130313A1 (en) | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | Imidazole derivatives as modulators of the gaba receptor for the treatment of gastrointestinal disorders |
US20090023704A1 (en) | 2007-04-18 | 2009-01-22 | Astrazeneca Ab | Novel Compounds 737 |
US20090088441A1 (en) | 2007-09-27 | 2009-04-02 | Leifeng Cheng | Quinoline Compounds |
US20090088439A1 (en) | 2007-09-27 | 2009-04-02 | Leifeng Cheng | Diazinane Compounds |
JP2015027951A (ja) | 2011-11-02 | 2015-02-12 | 日本農薬株式会社 | フタルアミド誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法 |
KR101348440B1 (ko) | 2011-12-14 | 2014-01-14 | 영남대학교 산학협력단 | 퀴나졸린-2,4-다이온 유도체의 원-팟 합성방법 |
-
2015
- 2015-05-04 TW TW104114119A patent/TW201623257A/zh unknown
- 2015-05-08 AU AU2015257540A patent/AU2015257540A1/en not_active Abandoned
- 2015-05-08 US US15/309,679 patent/US20170137387A1/en not_active Abandoned
- 2015-05-08 RU RU2016148170A patent/RU2016148170A/ru unknown
- 2015-05-08 JP JP2017510774A patent/JP2017514918A/ja active Pending
- 2015-05-08 CA CA2945217A patent/CA2945217A1/en not_active Abandoned
- 2015-05-08 WO PCT/FI2015/000020 patent/WO2015169999A1/en active Application Filing
- 2015-05-08 KR KR1020167034685A patent/KR20170002626A/ko unknown
- 2015-05-08 EP EP15726218.9A patent/EP3140301A1/en not_active Withdrawn
- 2015-05-08 CN CN201580026832.3A patent/CN106414430A/zh active Pending
- 2015-05-08 AR ARP150101421A patent/AR100360A1/es unknown
- 2015-05-08 MX MX2016014179A patent/MX2016014179A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2015257540A1 (en) | 2016-11-24 |
WO2015169999A8 (en) | 2015-12-23 |
KR20170002626A (ko) | 2017-01-06 |
US20170137387A1 (en) | 2017-05-18 |
TW201623257A (zh) | 2016-07-01 |
CA2945217A1 (en) | 2015-11-12 |
RU2016148170A (ru) | 2018-06-14 |
CN106414430A (zh) | 2017-02-15 |
EP3140301A1 (en) | 2017-03-15 |
JP2017514918A (ja) | 2017-06-08 |
AR100360A1 (es) | 2016-09-28 |
WO2015169999A1 (en) | 2015-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501720A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
PH12018501096A1 (en) | Modulators of chemokine receptors | |
DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
EA201892128A1 (ru) | Гетероциклические амиды, полезные в качестве модуляторов | |
MX2016014179A (es) | Derivados quinazolindiona farcologicamente activos. | |
MY172156A (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
MX2016005297A (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos. | |
EA201790785A1 (ru) | Производные тетрагидроизохинолина | |
EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
MX2015010106A (es) | Moduladores de la proteina activadora de 5-lipoxigenasa. | |
MX2017016619A (es) | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. | |
PH12017501280B1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
AU2015339087B2 (en) | Trifluoromethyl alcohols as modulators of RORyt | |
MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
MX2015008829A (es) | Momelotinib deuterado. | |
CR20170090A (es) | Derivados de terahidroquinolina como inhibidores del bromodominio | |
MX2015016766A (es) | Nuevos derivados de tetrazolona. | |
WO2015144977A8 (en) | Trpa1 modulators | |
MX2016006807A (es) | Derivados de imidazol. | |
MX2015012610A (es) | Pacritinib deuterizado. |